UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


         Date of Report (Date of earliest event reported): June 27, 2006


                          IMMTECH PHARMACEUTICALS, INC.
             (Exact Name of Registrant as Specified in its Charter)


         Delaware                      8733                   39-1523370
      (State or Other        (Commission File Number)      (I.R.S. Employer
      Jurisdiction of                                      Identification No.)
      Incorporation)


       One North End Avenue, New York, New York                  10282
       (Address of Principal Executive Offices)               (Zip Code)


      Registrant's telephone number, including area code:  (212) 791-2911


                                 Not Applicable
         (Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))


Item 5.02   Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers.

            On June 27, 2006, the Company received notice from Frederick W.
Wackerle of his decision to retire from the Company's board of directors to
devote more of his time to the not-for-profit sector. Mr. Wackerle will not
stand for re-election when his current term as a director expires at the 2006
Annual Meeting of Stockholders. He will remain a member of the Company's board
of directors until the earlier of that date or until a replacement director is
qualified and appointed. He stated that he wanted to give the Company sufficient
notice to find a qualified replacement and that his decision to retire from
service to the Company's board of directors is not a result of any disagreement
with the Company or management.

            Mr. Wackerle also notified the Company of his retirement from the
position of chairman of the Company's compensation committee. He has offered to
remain a member of the compensation committee until his retirement takes effect
as described above. Mr. Wackerle has been a member of the Company's board of
directors since December 2001 and has served on the Company's compensation and
nominating committees.

                                      -2-



                                   SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

                                         IMMTECH PHARMACEUTICALS, INC.


Date:  June 29, 2006                     By: /s/ Eric L. Sorkin
                                             --------------------------------
                                             Eric L. Sorkin
                                             Chief Executive Officer and
                                             President








                                      -3-